Case Reports in Oncology最新文献_第10页

A Rare Case of High-Grade Spindle Cell Sarcoma of the Breast: A Case Report. 一例罕见的乳腺高级别纺锤形细胞肉瘤：病例报告。

IF 0.8

Case Reports in Oncology Pub Date : 2024-02-08 eCollection Date: 2024-01-01 DOI: 10.1159/000536125

Zoaib Habib Tharwani, Zehra Habib, Yumna Ahmed, Samreena Ishrat, Abdulqadir J Nashwan

{"title":"A Rare Case of High-Grade Spindle Cell Sarcoma of the Breast: A Case Report.","authors":"Zoaib Habib Tharwani, Zehra Habib, Yumna Ahmed, Samreena Ishrat, Abdulqadir J Nashwan","doi":"10.1159/000536125","DOIUrl":"10.1159/000536125","url":null,"abstract":"Introduction: Spindle cell sarcomas are rare breast lesions which are difficult to diagnose due to resemblance with other breast lesions. Histopathological examination and immunohistochemical staining are essential for diagnosis.Case presentation: We present a rare case of a 15-year-old female presenting with high-grade rapidly progressive spindle cell sarcoma of the breast, differentiated as phyllodes tumor, with axillary lymph node involvement. Her lesion, on the left breast, measured 16.9 × 10.1 × 13.7 cm. Histology revealed malignant neoplasm arranged in sheets and individual neoplastic cells with an epithelioid to spindled morphology with scant cytoplasm and irregular nuclear membranes. Immunohistochemistry showed weakly positive focal CD-99, and negative WT-1, Myogenin, Desmin, p63, Cytokeratin, Synaptophysin, and CD-34 markers. She was successfully managed with modified radical mastectomy and discharged with regular follow-up advised.Conclusion: Spindle cell sarcomas have a very aggressive course and prompt diagnosis, and management is mandatory for better patient outcomes. Modified radical mastectomy is the mainstay of treatment.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10852984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139706160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Complexities in Adjuvant Endocrine Therapy for Breast Cancer in Female-to-Male Transgender Patients. 女变男变性患者乳腺癌辅助内分泌治疗的复杂性。

IF 0.8

Case Reports in Oncology Pub Date : 2024-02-07 eCollection Date: 2024-01-01 DOI: 10.1159/000536212

Shoko Sato, Sae Imada, Ryosuke Hayami, Kazumori Arai, Rieko Kosugi, Michiko Tsuneizumi, Ryoichi Matsunuma

引用次数: 0

Rare Delayed Ifosfamide Encephalopathy: A Case Report of Chemotherapeutic Neurotoxicity. 罕见的迟发性伊福酰胺脑病：化疗神经毒性病例报告

IF 0.8

Case Reports in Oncology Pub Date : 2024-02-06 eCollection Date: 2024-01-01 DOI: 10.1159/000535952

Ambika Menon, Chidiebele A Enunwa, William L Read, Kyle P James

{"title":"Rare Delayed Ifosfamide Encephalopathy: A Case Report of Chemotherapeutic Neurotoxicity.","authors":"Ambika Menon, Chidiebele A Enunwa, William L Read, Kyle P James","doi":"10.1159/000535952","DOIUrl":"10.1159/000535952","url":null,"abstract":"Introduction: Neurotoxicity is a well-documented side effect of ifosfamide chemotherapy. The presentation includes hallucinations, seizures, disorientation, coma, and death. Treatment with methylene blue can shorten the duration and severity of symptoms. Ifosfamide neurotoxicity almost always happens during or shortly after drug infusion and so is usually immediately recognized. Here, we describe a case of ifosfamide neurotoxicity with onset 14 days after treatment started.Case presentation: A 25-year-old woman with round cell sarcoma of the jaw presented to the emergency department with 2 days of encephalopathy and bizarre behavior. Antipsychotic medications and benzodiazepines produced no benefit. After consultation, oncology recommended methylene blue, hypothesizing that her symptoms could be a rare presentation of delayed ifosfamide-induced neurotoxicity, 14 days after first administration. After 4 days of methylene blue infusion, her functioning returned to baseline.Conclusion: Delayed ifosfamide-related neurotoxicity is a rare side effect of this chemotherapeutic agent and should be considered in the workup of altered mental status, even if symptoms occur after the previously accepted 5-day standard. In such patients, delayed symptomology may require extended use of methylene blue as treatment.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10846873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139696943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Severe Colitis in 2 Patients with Melanoma Treated with BRAF/MEK Inhibitors: Case Report and Literature Review. 两名接受 BRAF/MEK 抑制剂治疗的黑色素瘤患者出现严重结肠炎：病例报告和文献综述。

IF 0.8

Case Reports in Oncology Pub Date : 2024-02-02 eCollection Date: 2024-01-01 DOI: 10.1159/000535741

Chloe Wautier, Jolanta Gourmaud, Catherine Dong, Gregoire Berthod

{"title":"Severe Colitis in 2 Patients with Melanoma Treated with BRAF/MEK Inhibitors: Case Report and Literature Review.","authors":"Chloe Wautier, Jolanta Gourmaud, Catherine Dong, Gregoire Berthod","doi":"10.1159/000535741","DOIUrl":"10.1159/000535741","url":null,"abstract":"Introduction: Encorafenib and binimetinib, a combination of BRAF and MEK inhibitors, is a standard of care for patients with advanced BRAFV600-mutant melanoma. This combination is known to have gastrointestinal side effects, most of which are mild and managed symptomatically. However, very few studies have reported severe colitis.Case presentation: We report here 2 patients with advanced melanoma who developed severe ulcerated right colitis manifested by diarrhea and hematochezia while being treated with encorafenib and binimetinib after immune checkpoint therapy.Conclusion: This rare but serious adverse event was not described in early phase 3 trials but has emerged in recent years, particularly with the sequential use of immune checkpoint inhibitors followed by BRAF/MEK inhibitors. In a comprehensive review of the existing literature, we identified 20 cases of severe colitis due to BRAF/MEK inhibitors. Clinical, endoscopic, and histological features are described to provide insight into the current understanding of this poorly understood clinical entity.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10836952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139680662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Removal of a Metallic Stent after 9 Years of Placement That Caused Tracheal Stenosis: A Rare Case Report. 金属支架放置 9 年后导致气管狭窄而被移除：罕见病例报告

IF 0.8

Case Reports in Oncology Pub Date : 2024-02-02 eCollection Date: 2024-01-01 DOI: 10.1159/000536213

Torahiko Nakashima, Koji Yamazaki, Ryutaro Uchi, Hideoki Uryu

{"title":"Removal of a Metallic Stent after 9 Years of Placement That Caused Tracheal Stenosis: A Rare Case Report.","authors":"Torahiko Nakashima, Koji Yamazaki, Ryutaro Uchi, Hideoki Uryu","doi":"10.1159/000536213","DOIUrl":"10.1159/000536213","url":null,"abstract":"Introduction: Metallic stents are widely used to prevent airway obstruction for tracheal stenosis caused by malignant diseases. Although their efficacy has been recognized, there is no established evidence surrounding their long-term safety. We report a case of airway stenosis caused by a metallic tracheal stent. Removal of the stent to secure the airway was difficult and extremely complicated.Case presentation: A 50-year-old male suffering from dyspnea caused by malignant lymphoma (diffuse large B-cell lymphoma) of the thyroid gland was treated with a metallic tracheal stent. After remission of the lymphoma, stenosis of the stent lumen developed gradually, and the patient complained of dyspnea. Tracheostomy could not be performed due to the metallic stent. Since the patient was unable to intubate, the stent was removed under general anesthesia with partial percutaneous cardiopulmonary support 9 years after the stent placement.Conclusion: Otolaryngologists should be aware of the possibility of severe stenosis following the long-term placement of a metallic tracheal stent.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10836946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139680661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lemierre's Syndrome after Head and Neck Photoimmunotherapy for Local Recurrence of Nasopharyngeal Carcinoma. 头颈部光免疫疗法治疗鼻咽癌局部复发后的莱米尔综合征

IF 0.8

Case Reports in Oncology Pub Date : 2024-02-01 eCollection Date: 2024-01-01 DOI: 10.1159/000535597

Midori Nishimura, Isaku Okamoto, Tatsuya Ito, Kunihiko Tokashiki, Kiyoaki Tsukahara

{"title":"Lemierre's Syndrome after Head and Neck Photoimmunotherapy for Local Recurrence of Nasopharyngeal Carcinoma.","authors":"Midori Nishimura, Isaku Okamoto, Tatsuya Ito, Kunihiko Tokashiki, Kiyoaki Tsukahara","doi":"10.1159/000535597","DOIUrl":"https://doi.org/10.1159/000535597","url":null,"abstract":"Introduction: Head and neck photoimmunotherapy (HN-PIT) uses a combination of drugs and laser illumination to specifically destroy tumor cells. Lemierre's syndrome is an infectious disease with severe systemic symptoms caused by prior infection in the pharyngeal region, leading to thrombophlebitis. Here, we report a case of Lemierre's syndrome that developed after HN-PIT for recurrent nasopharyngeal carcinoma.Case presentation: A 68-year-old male with nasopharyngeal carcinoma (squamous cell carcinoma) underwent HN-PIT after local recurrence with chemoradiation therapy. Three months after HN-PIT, the patient developed fever and neck pain, which led to a diagnosis of Lemierre's syndrome. The patient was treated with antibiotics and anticoagulants for at least 1 month. The patient's general condition and inflammatory findings on blood sampling showed gradual improvement, and a follow-up cervicothoracic computed tomography imaging showed that the venous thrombus had been obscured and the patient was doing well.Conclusion: HN-PIT is a high-risk procedure for the development of Lemierre's syndrome due to irradiation-induced mucositis, and anticipating the development of Lemierre's syndrome during HN-PIT is important.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10834035/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139671379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Complete Remission in a TEMPI Syndrome Treated with a Daratumumab, Lenalidomide, and Dexamethasone-Based Regimen: A Case Report. 用达拉单抗、来那度胺和地塞米松为基础的治疗方案治疗 TEMPI 综合征，患者病情完全缓解：病例报告。

IF 0.8

Case Reports in Oncology Pub Date : 2024-01-31 eCollection Date: 2024-01-01 DOI: 10.1159/000535551

Pierre-Yves Sansen, Luc Montfort, Anne Nanquette, Julien Depaus, Hélène Vellemans

{"title":"Complete Remission in a TEMPI Syndrome Treated with a Daratumumab, Lenalidomide, and Dexamethasone-Based Regimen: A Case Report.","authors":"Pierre-Yves Sansen, Luc Montfort, Anne Nanquette, Julien Depaus, Hélène Vellemans","doi":"10.1159/000535551","DOIUrl":"10.1159/000535551","url":null,"abstract":"Introduction: TEMPI syndrome is a rare and acquired condition which is characterized by five classical features: telangiectasias, erythrocytosis with elevated erythropoietin, monoclonal gammopathy, perinephric fluid collections, and intrapulmonary shunting. The classical treatment is based on bortezomib which can achieve variable responses. Relapse or refractory disease may occur, so other treatment strategies can be proposed.Case presentation: We describe the case of a 54-year-old male followed for a refractory TEMPI syndrome who achieved complete remission after a second-line therapy composed of daratumumab-, lenalidomide-, and dexamethasone-based regimen (DLd). He achieved a complete remission with dramatic improvement of his renal function, restitution of a normal blood oxygen, and disappearance of polycythemia.Conclusion: This case highlights the effectiveness of an association of DLd to treat refractory TEMPI syndrome. We also provide arguments for an association between TEMPI syndrome and monoclonal gammopathy of renal significance.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10830137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139650303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Case of Successful Treatment with an Immune Checkpoint Inhibitor after Head and Neck Photoimmunotherapy. 头颈部光免疫疗法后使用免疫检查点抑制剂成功治疗的案例。

IF 0.8

Case Reports in Oncology Pub Date : 2024-01-30 eCollection Date: 2024-01-01 DOI: 10.1159/000536166

Kenji Hanyu, Isaku Okamoto, Kunihiko Tokashiki, Kiyoaki Tsukahara

{"title":"A Case of Successful Treatment with an Immune Checkpoint Inhibitor after Head and Neck Photoimmunotherapy.","authors":"Kenji Hanyu, Isaku Okamoto, Kunihiko Tokashiki, Kiyoaki Tsukahara","doi":"10.1159/000536166","DOIUrl":"10.1159/000536166","url":null,"abstract":"Introduction: Head and neck photoimmunotherapy (HN-PIT) has been conditionally approved by the Japanese government for the treatment of unresectable locally advanced or locally recurrent head and neck cancer since January 2021. HN-PIT makes local treatment of locally recurrent disease possible in cases where systemic drug therapy would have previously been the only option. However, when treatment is ineffective and the disease progresses, it is necessary to shift to conventional drug therapies. We report a case in which an immune checkpoint inhibitor (ICI) was successfully administered to a patient with advanced disease following HN-PIT.Case presentation: A 75-year-old male patient presented with local recurrence of mandibular gingival cancer. The primary treatment consisted of mandibular segmentectomy and reconstruction with a scapulohumeral and vastus lateralis skin valve. Post-operative radiotherapy was administered. Local recurrence was found in the mid-pharynx adjacent to the reconstruction. HN-PIT was performed for the local recurrence. After three cycles of HN-PIT, the local lesion increased, and the disease was evaluated as advanced. Therefore, the patient was switched to pembrolizumab, an ICI.Conclusion: The recurrent lesions disappeared 2 months after the first dose of pembrolizumab, and the patient remained in clinical remission at 1 year. To the best of our knowledge, there are no other reports of successful ICI therapy after HN-PIT.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10827299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139641670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma. BRAF-V600突变转移性黑色素瘤患者对二线Nivolumab和Ipilimumab的显著反应

IF 0.8

Case Reports in Oncology Pub Date : 2024-01-29 eCollection Date: 2024-01-01 DOI: 10.1159/000535902

Dahlia Fedele, Stefano Moroso, Angelo Turoldo, Gabriele Bazzocchi, Claudio Conforti, Iris Zalaudek, Alessandra Guglielmi

{"title":"A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma.","authors":"Dahlia Fedele, Stefano Moroso, Angelo Turoldo, Gabriele Bazzocchi, Claudio Conforti, Iris Zalaudek, Alessandra Guglielmi","doi":"10.1159/000535902","DOIUrl":"10.1159/000535902","url":null,"abstract":"Introduction: Current treatment options for BRAF V600-mutated unresectable stage III/IV melanoma include anti-PD-1 monotherapy or combination with anti-CTLA-4 or anti-LAG-3 agents, BRAF/MEK inhibitors, and clinical trials. The strategy of combination immunotherapy with nivolumab and ipilimumab has shown promising results, achieving higher response rates, longer duration of response, improved progression-free survival, and enhanced overall survival. The optimal sequence of treatments remains a topic of interest, with preliminary data suggesting a greater effectiveness of immunotherapy as the first-line approach. Preclinical trials have indicated that the efficacy of this sequence may be due to the modification of the immune environment by BRAF kinase inhibitors, leading to immune escape by tumor cells and resistance to immune checkpoint inhibitors.Case presentation: We present a case of a 72-year-old woman with high-burden metastatic melanoma who failed to respond to prior targeted therapy with BRAF/MEK inhibitors and exhibited a successful response to the second-line treatment with ipilimumab and nivolumab. We discuss the potential reasons for this positive outcome contributing to the current debate concerning treatment sequences, resistance mechanisms, and biomarkers predictive of response to immune checkpoint inhibitors in metastatic melanoma.Conclusion: We believe that in few years the therapeutic algorithms in BRAF V600-mutated unresectable stage III/IV melanoma will be more complex since they will define clearly the correct therapeutic sequences with the inclusion of new immune checkpoint inhibitor drugs and multiple predictive biomarkers of response to better select patients eligible to immunotherapy.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10824524/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139575263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HER2-Positive Lacrimal Sac Squamous Cell Carcinoma in a 57-Year-Old Man. 一名 57 岁男子的 HER2 阳性泪囊鳞状细胞癌

IF 0.8

Case Reports in Oncology Pub Date : 2024-01-29 eCollection Date: 2024-01-01 DOI: 10.1159/000536061

Nikolay Grachev, Gavriil Rabaev, Ashot Avdalyan, Igor Znamenskiy, Dmitry Mosin, Dmitry Ustyuzhanin, Gennady Rabaev, Martin Lužbeták

引用次数: 0